Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

Study Drug Administration:

If participant is found to be eligible to take part in this study, participant will take
rigosertib capsules by mouth 2 times each day (1 morning dose, 1 afternoon dose) for 48
weeks. Participant will take participant's morning dose on an empty stomach. Participant's
afternoon dose should be taken at about 3:00 pm (±1 hour), at least 2 hours after lunch.
Participant should drink at least a ½ gallon of water each day. Rigosertib should be
refrigerated.

Participant will also be given a study drug diary. Participant should write down each dose of
study drug that participant takes, when participant takes it, and if participant misses or
vomit any doses. If participant misses or vomits a dose of rigosertib, participant should not
make up the dose. Participant should take the next scheduled dose as planned. Every 4 weeks
for 12 weeks, then every 8 weeks thereafter, participant should bring any leftover rigosertib
capsules and participant's study drug diary with participant to the clinic.

Study Visits:

On Cycle 1 Day 1:

- Participant will have a physical exam.

- Blood (about 2-3 teaspoons) and urine will be collected for routine tests.

- Blood (about 2 teaspoons) will be drawn for pharmacokinetic (PK) testing about 1 hour
after participant's dose of study drug. PK testing measures the amount of study drug in
the body at different time points.

- Participant will complete a questionnaire about participant's quality of life. It should
take about 10-15 minutes.

- If the doctor thinks it is needed, participant will have a computed tomography (CT) or
magnetic resonance imaging (MRI) scan to check the status of the disease.

Each week, blood (about 2-3 teaspoons) will be drawn for routine tests. If the study doctor
approves it, participant may have these weekly blood draws at a local lab closer to
participant's home. The results from these routine tests will be sent to the study doctor.

On Day 1 of Week 4, blood (about 2 teaspoons each time) will be drawn for PK testing before
and 1 hour after participant's dose of study drug.

At Weeks 24 and 48 (± 1 week):

- Participant will have a bone marrow aspirate/biopsy performed to check the status of the
disease. This sample may also be used for cytogenetic testing.

- If participant had a CT/MRI scan performed during Week 1, participant will have another
CT/MRI scan to check the status of the disease.

- If participant can become pregnant, urine will be collected for a pregnancy test.

Every 4 weeks until Week 12 and then every 8 weeks after that:

- Participant will have a physical exam.

- Blood (about 2-3 teaspoons) and urine will be collected for routine tests.

- Participant will complete a questionnaire about participant's quality of life.

Length of Study:

Participant may continue taking the study drug for up to 48 weeks. Participant will no longer
be able to take the study drugs if the disease gets worse, if intolerable side effects occur,
or if participant is unable to follow study directions.

If the doctor thinks it is in participant's best interest, participant may be able to
continue taking the study drug after 48 weeks. The study doctor will discuss this with
participant.

Participation on the study will be over after the end-of-study visit.

End-of-Study Visit:

About 4 weeks after participant's last dose of study drug, participant will have an
end-of-study visit. At this visit:

- Participant will have a physical exam.

- Blood (about 2-3 teaspoons) and urine will be collected for routine tests. This routine
blood and urine collection will also include a pregnancy test if participant can become
pregnant.

Inclusion Criteria:

1. >/= 18 years of age;

2. Diagnosis of primary myelofibrosis (PMF) or post-polycythemia vera (post-PV) MF or
post-essential thrombocythemia (post-ET) MF based on the World Health Organization
(WHO) criteria or the IWG-MRT criteria, which must be confirmed by BM aspirate and/or
biopsy within 6 weeks prior to Screening. Measurement of JAK2 V617F allele burden in
BM samples, if not done within 6 months prior to Screening, must be provided with the
Screening BM biopsy/aspirate report (patients are eligible regardless of JAK2 mutation
status);

3. Anemia or RBC-transfusion dependence defined as follows: a) Anemia: defined for the
purpose of this protocol as 1) a hemoglobin level <10 g/L on every determination over
84 days before study-entry, without RBC-transfusions, or 2) a hemoglobin level <10 g/L
on a patient that is receiving RBC-transfusions periodically but not meeting criteria
for transfusion-dependent patient as defined below. The baseline hemoglobin value for
these subjects is the lowest hemoglobin level during the antecedent 84 days; b)
RBC-transfusion-dependence: RBC-transfusion-frequency of >/=2 units PRBC/28 days
averaged over 84 days immediately pre-study-entry. There must not be any consecutive
42 days without an RBC-transfusion during this interval.

4. ECOG performance status of 0, 1 or 2;

5. Willing to adhere to the prohibitions and restrictions specified in this protocol
(Notation: the subject's willingness to adhere to prohibitions and restrictions must
be clearly communicated in the on-study note);

6. The patient must signed an informed consent form (ICF) indicating that s/he
understands the purpose of, and procedures required for, the study and is willing to
participate.

Exclusion Criteria:

1. Ongoing clinically significant anemia due to factors such as known iron, vitamin B12,
or folate deficiencies, auto-immune or hereditary hemolysis, or gastrointestinal (GI)
bleeding;

2. Serum ferritin < 50 ng/mL;

3. Any active malignancy within the past year, except basal cell or squamous cell skin
cancer or carcinoma in situ of the cervix or breast; patients with history of prior
malignancies should be free of disease for at least 3 years to be eligible for this
study.

4. Uncontrolled intercurrent illness, including, but not limited to symptomatic
congestive heart failure, unstable angina pectoris, or cardiac arrhythmia;

5. Active infection not adequately responding to appropriate therapy;

6. Direct bilirubin >/= 2.0 mg/dL not related to hemolysis or Gilbert's disease;

7. Alanine transaminase (ALT) or aspartate transaminase (AST)>/= 2.5 x the upper limit of
normal (ULN);

8. Serum creatinine >/= 2.5 mg/dL;

9. Ascites requiring active medical management including paracentesis;

10. Hyponatremia (defined as serum sodium level < 130 mEq/L);

11. Female patients who are pregnant or lactating;

12. Patients of childbearing potential (ie, women of childbearing potential and men with
female partners of childbearing potential) who are unwilling to follow strict
contraception requirements (including 2 reliable methods in combination: 1
non-hormonal, highly-reliable method [diaphragm, condoms with spermicidal foam or
jelly, or sterilization] plus 1 additional reliable method [birth control pills,
intrauterine device, contraceptive injections, or contraceptive patches]) before entry
and throughout the study, up to and including the 30-day non-treatment follow-up
period;

13. Female patients of childbearing potential who have a positive blood or urine pregnancy
test at Screening;

14. Major surgery without full recovery or major surgery within 3 weeks of Screening;

15. Uncontrolled hypertension (defined as a sustained systolic pressure >/= 160 mmHg
and/or a diastolic pressure >/= 110 mmHg);

16. New onset seizures (within 3 months prior to Screening) or poorly controlled seizures;

17. Any other concurrent investigational agent or chemotherapy, radiotherapy, or
immunotherapy;

18. Chronic use (> 2 weeks) of corticosteroids (prednisone >/= 10 mg/24 hr equivalent)
within 4 weeks of Screening;

19. Investigational therapy within 2 weeks of Screening;

20. Psychiatric illness or social situation that would limit the patient's ability to
tolerate and/or comply with study requirements.